Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial

BACKGROUND: The emergence of new molecular targeted drugs provides new prospects for the treatment of advanced breast cancer; the future therapeutic trend includes chemotherapy combined with molecular targeted therapy. Apatinib mesylate, a novel, small anti-angiogenic agent, highly selectively inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shuo, Zhang, Liang, Li, Huan, Xu, Junnan, Jiang, Cui, Sun, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245760/
https://www.ncbi.nlm.nih.gov/pubmed/32448335
http://dx.doi.org/10.1186/s13063-020-04342-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245760/
https://www.ncbi.nlm.nih.gov/pubmed/32448335
http://dx.doi.org/10.1186/s13063-020-04342-x

Ejemplares similares